Roivant reported Phase 2 success for mosliciguat, an inhaled therapy for interstitial lung disease, meeting key endpoints in a 16-week study. The company said mosliciguat achieved a statistically significant 56% placebo-adjusted reduction in pulmonary vascular resistance, alongside improvements in six-minute walk distance and NT-proBNP. The readout follows Roivant’s acquisition of mosliciguat from Bayer, and it is positioned as a potential growth driver for the company as additional clinical milestones approach. A positive mid-stage outcome can strengthen near-term partnering optionality and improve financing leverage for later development steps. For biotech, the impact centers on inhaled vasculature-targeting strategies and the competitive landscape of pulmonary hypertension and related cardiopulmonary indications. Mosliciguat’s progression suggests more momentum for inhaled small molecules targeting cardiopulmonary physiology rather than systemic agents.